ALC vs VRDN
Alcon Inc vs Viridian Therapeutics, Inc. — AI-powered side-by-side comparison
VS
VRDN
Viridian Therapeutics, Inc.
64
Buy
| Metric | ALC | VRDN |
|---|
| AI Score |
68
|
64
|
| Price |
$75.39
|
$23.00
|
| P/E Ratio |
45.39×
|
-6.28×
|
| ROE |
4.4%
|
-47.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
99.4%
|
| Debt / Equity |
0.24×
|
0.37×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
74.5
|
| Beta |
0.703
|
0.94
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus VRDN.
ALC leads by 4 points.
ALC scores 68/100 (Buy) versus VRDN at 64/100 (Buy).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
VRDN Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 23220.3% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.1x prices in significant intangible value — Value
- ROE of only -61.4% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical